NO20005224L - BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse - Google Patents

BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse

Info

Publication number
NO20005224L
NO20005224L NO20005224A NO20005224A NO20005224L NO 20005224 L NO20005224 L NO 20005224L NO 20005224 A NO20005224 A NO 20005224A NO 20005224 A NO20005224 A NO 20005224A NO 20005224 L NO20005224 L NO 20005224L
Authority
NO
Norway
Prior art keywords
identification
methods
btk inhibitors
inhibitors
btk
Prior art date
Application number
NO20005224A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005224D0 (no
Inventor
Faith M Uckun
Yaguo Zheng
Sutapa Ghosh
Original Assignee
Parkes Hughes Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/273,191 external-priority patent/US6303652B1/en
Application filed by Parkes Hughes Inst filed Critical Parkes Hughes Inst
Publication of NO20005224D0 publication Critical patent/NO20005224D0/no
Publication of NO20005224L publication Critical patent/NO20005224L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20005224A 1998-04-17 2000-10-17 BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse NO20005224L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8209498P 1998-04-17 1998-04-17
US09/273,191 US6303652B1 (en) 1998-08-21 1999-03-19 BTK inhibitors and methods for their identification and use
PCT/US1999/008556 WO1999054286A2 (en) 1998-04-17 1999-04-19 Btk inhibitors and methods for their identification and use

Publications (2)

Publication Number Publication Date
NO20005224D0 NO20005224D0 (no) 2000-10-17
NO20005224L true NO20005224L (no) 2000-12-18

Family

ID=26767041

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005224A NO20005224L (no) 1998-04-17 2000-10-17 BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse

Country Status (13)

Country Link
EP (1) EP1071658B1 (de)
JP (1) JP2002512216A (de)
KR (1) KR20010042804A (de)
AT (1) ATE269295T1 (de)
AU (1) AU3653099A (de)
CA (1) CA2328962A1 (de)
DE (1) DE69918089T2 (de)
ES (1) ES2222705T3 (de)
HU (1) HUP0102661A2 (de)
IL (1) IL139080A0 (de)
MX (1) MXPA00010150A (de)
NO (1) NO20005224L (de)
WO (1) WO1999054286A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6306897B1 (en) * 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
EP1230232B1 (de) 1999-11-05 2004-02-25 Cytovia, Inc. Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
CA2390857A1 (en) * 1999-11-30 2001-06-14 Fatih M. Uckun Inhibitors of collagen-induced platelet aggregation
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
AU2001236361A1 (en) * 2000-10-20 2002-05-06 Parker Hughes Institute Treatment of asthma with lfm analogues
JP2004533209A (ja) * 2000-10-23 2004-11-04 ブリストル−マイヤーズ　スクイブ　カンパニー ブルトンチロシンキナーゼおよびブルトンチロシンキナーゼ媒体のモデュレーターおよびその同定方法および骨粗鬆症および関連疾患状態の治療および予防におけるその使用
DE60221104T2 (de) * 2001-03-07 2008-03-13 TELIK, INC., Palo Alto Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
CA2441088A1 (en) * 2001-03-13 2002-09-19 Protagen Ag 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof
US6858607B1 (en) 2001-05-16 2005-02-22 Cytovia, Inc. 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2447010C (en) 2001-05-16 2011-08-02 Cytovia, Inc. Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2002092076A1 (en) * 2001-05-16 2002-11-21 Cytovia, Inc. Substituted coumarins and quinolines as caspases activators
WO2003027320A2 (en) * 2001-09-24 2003-04-03 University Of Aarhus Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
WO2003096982A2 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4h-chromenes, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
CA2484702A1 (en) 2002-05-16 2003-11-27 Cytovia, Inc. Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2004024676A1 (de) * 2002-09-06 2004-03-25 Schebo®Biotech Ag Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
EP1804782A1 (de) * 2004-10-19 2007-07-11 Aventis Pharmaceuticals Inc. Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung entzündlicher darmerkrankungen
WO2008033858A2 (en) * 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
EP2526934B1 (de) 2006-09-22 2015-12-09 Pharmacyclics LLC Hemmer der Bruton-Tyrosinkinase
EP2546651A1 (de) * 2007-03-14 2013-01-16 Bionsil S.r.l. Modulatorverbindungen der Arzneimittelresistenz in Epitheltumorzellen
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2701275C (en) * 2007-10-23 2016-06-21 F. Hoffmann-La Roche Ag Kinase inhibitors
WO2009060835A1 (ja) * 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
US8389757B2 (en) 2008-06-05 2013-03-05 Alembic Ltd. Process for preparing teriflunomide
ES2660418T3 (es) 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
MX388981B (es) 2010-04-05 2025-03-20 Fosun Orinove Pharmatech Inc Inhibidores de enzima 1 dependiente de inositol (ire-1alfa).
CA3240281A1 (en) 2010-06-03 2011-12-08 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
JP2014520863A (ja) 2011-07-13 2014-08-25 ファーマサイクリックス，インク． Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
NZ713828A (en) 2012-06-04 2017-05-26 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
CA2890934A1 (en) 2012-11-15 2014-05-22 Pharmacyclics, Inc. Pyrrolopyrimidine compounds as kinase inhibitors
US10876096B2 (en) 2012-11-28 2020-12-29 Corning Incorporated Cell culture medium for enhanced hepatocyte function
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
KR101737723B1 (ko) 2013-04-02 2017-05-18 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
CA2919996A1 (en) 2013-08-02 2015-02-05 Pharmacyclics Llc Methods for the treatment of solid tumors
EP2832358A1 (de) * 2013-08-02 2015-02-04 Bionsil S.r.l. Pharmazeutisches Kit zur Verwendung bei der Behandlung von Darm- und kolorektalem Krebs
US9415050B2 (en) 2013-08-12 2016-08-16 Pharmacyclics Llc Methods for the treatment of HER2 amplified cancer
PE20160560A1 (es) 2013-09-30 2016-06-09 Pharmacyclics Llc DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK)
WO2015089481A2 (en) 2013-12-13 2015-06-18 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体（上海）有限公司 一种环保简便制备泰瑞米特的方法
AU2015296215A1 (en) 2014-08-01 2017-03-23 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
RU2017106795A (ru) 2014-08-07 2018-09-07 Фармасайкликс Элэлси Новые составы ингибитора тирозинкиназы брутона
EP3715346B1 (de) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolylhaltige verbindungen zur behandlung proliferativer erkrankungen
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP7305352B2 (ja) 2016-03-31 2023-07-10 武田薬品工業株式会社 イソキノリニルトリアゾロン錯体
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
EP3942045A1 (de) 2019-03-21 2022-01-26 Onxeo Dbait-molekül in kombination mit einem kinaseinhibitor zur behandlung von krebs
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2555685A1 (de) * 1975-12-11 1977-06-23 Hoechst Ag Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
EP0527736B1 (de) * 1990-05-18 1997-04-16 Hoechst Aktiengesellschaft Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
CA2080554A1 (en) * 1991-10-15 1993-04-16 Mitsubishi Chemical Corporation Styrene derivatives
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
EP0674643A1 (de) * 1992-12-23 1995-10-04 Smithkline Beecham Corporation Cumarin-derivate als retrovirale inhibitoren
GB9322781D0 (en) * 1993-11-04 1993-12-22 Roussel Lab Ltd Aromatic amides
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5489697A (en) * 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
US5608085A (en) * 1995-02-27 1997-03-04 The University Of Tennessee Research Corporation Synthesis of optically active calanolides A and B and enantiomers and related compounds
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
IT1289238B1 (it) * 1996-12-10 1998-09-29 Bio S S P A Ora Bio S S R L Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina

Also Published As

Publication number Publication date
EP1071658A2 (de) 2001-01-31
HUP0102661A2 (hu) 2001-11-28
WO1999054286A3 (en) 2000-05-04
IL139080A0 (en) 2001-11-25
MXPA00010150A (es) 2002-05-14
JP2002512216A (ja) 2002-04-23
NO20005224D0 (no) 2000-10-17
AU3653099A (en) 1999-11-08
KR20010042804A (ko) 2001-05-25
ATE269295T1 (de) 2004-07-15
DE69918089T2 (de) 2005-07-14
CA2328962A1 (en) 1999-10-28
ES2222705T3 (es) 2005-02-01
EP1071658B1 (de) 2004-06-16
WO1999054286A2 (en) 1999-10-28
DE69918089D1 (de) 2004-07-22

Similar Documents

Publication Publication Date Title
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
DE60007095D1 (de) Calanolide zur hemmung von btk
TR200100054T2 (tr) Paroksetin metansülfonat
DK1268431T3 (da) 3-Cyanoquinoliner, 3-cyano-1,6-naphthyridiner og 3-cyano-1,7-naphthyridiner som proteinkinaseinhibitorer
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
BR0317715A (pt) Composições e processos de uso de collajolie
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
DK1114032T3 (da) 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer
DK0965578T3 (da) Hidtil ukendt triglycerik og præparat, som omfatter dette
NO20053356D0 (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
ATE231872T1 (de) Thiazolopyrimidinderivate
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
NO980178L (no) Cyklo-oksygenase-inhibitor og amidin-derivatsalter, fremgangsmåte for fremstilling derav, anvendelse derav som legemidler, og farmasöytiske blandinger inneholdende slike derivater
DK1322158T3 (da) Farmaceutiske præparater med langvarig frigivelse, som indeholder metformin, og fremgangsmåde til fremstilling deraf
NO20041432D0 (no) Sammensetninger som innbefatter COX-2 inhibitorer og aspirin.
NO20013853D0 (no) Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer
DK1214302T3 (da) Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-oner og deres anvendelse som lipasehæmmere
NO981019D0 (no) Deodoriserende preparater inneholdende kationiske biopolymerer, aluminiumklorhydrat og esteraseinhibitorer
NO20033921L (no) Inhibitor av monoaminopptak
NO20060065L (no) Tabletter inneholdende enrofloksacin og smaks- og/eller aromastoffer
DE60207833D1 (de) Peptiddeformylase-hemmer
SE0100374D0 (sv) Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
BR0308321A (pt) Inibidores da peptìdeo deformilase
DE60232650D1 (de) Peptiddeformylaseinhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application